Artemisinin
Star6
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Artemisinin is a medication indicated in the treatment of malaria.
- Generic Name
- Artemisinin
- DrugBank Accession Number
- DB13132
- Background
Artemisinin has been used in trials studying the treatment of Schizophrenia, Malaria, Falciparum, and Plasmodium Falciparum.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 282.336
Monoisotopic: 282.146723808 - Chemical Formula
- C15H22O5
- Synonyms
- Artemisinin
- artemisinina
- External IDs
- NSC-369397
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Malaria caused by plasmodium falciparum Combination Product in combination with: Piperaquine (DB13941) •••••••••••• ••••••• •••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Artemisinin can be increased when it is combined with Abametapir. Abatacept The metabolism of Artemisinin can be increased when combined with Abatacept. Acetophenazine The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Acetophenazine. Adalimumab The metabolism of Artemisinin can be increased when combined with Adalimumab. Alimemazine The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Alimemazine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- P01BF08 — Artemisinin and naphthoquine
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- P01BF — Artemisinin and derivatives, combinations
- P01B — ANTIMALARIALS
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- Drug Categories
- Anti-Infective Agents
- Antimalarials
- Antiparasitic Products, Insecticides and Repellents
- Antiprotozoals
- Artemisia
- Artemisinin and derivatives
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2B6 Inducers (strength unknown)
- Cytochrome P-450 CYP2B6 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Substrates
- Free Radicals
- Peroxides
- Reactive Oxygen Species
- Sesquiterpenes
- Terpenes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as terpene lactones. These are prenol lipids containing a lactone ring.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Terpene lactones
- Direct Parent
- Terpene lactones
- Alternative Parents
- Artemisinins / Oxepanes / Delta valerolactones / Trioxanes / Oxanes / Dialkyl peroxides / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Acetals show 2 more
- Substituents
- 1,2,4-trioxane / Acetal / Aliphatic heteropolycyclic compound / Artemisinin skeleton / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Delta valerolactone / Delta_valerolactone / Dialkyl peroxide show 12 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- organic peroxide, sesquiterpene lactone (CHEBI:223316) / Eudesmane sesquiterpenoids, Sesquiterpenoids (C15) (C09538) / Eudesmane sesquiterpenoids (LMPR0103190003)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9RMU91N5K2
- CAS number
- 63968-64-9
- InChI Key
- BLUAFEHZUWYNDE-NNWCWBAJSA-N
- InChI
- InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
- IUPAC Name
- (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecan-10-one
- SMILES
- [H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C(=O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4
References
- General References
- Not Available
- External Links
- KEGG Compound
- C09538
- PubChem Compound
- 68827
- PubChem Substance
- 347829251
- ChemSpider
- 62060
- BindingDB
- 50088447
- 2367409
- ChEBI
- 223316
- ChEMBL
- CHEMBL269671
- ZINC
- ZINC000008143788
- PharmGKB
- PA165111696
- Wikipedia
- Artemisinin
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Malaria caused by Plasmodium falciparum / Plasmodium Falciparum 1 3 Completed Treatment Schizophrenia 1 2 Not Yet Recruiting Treatment Anal High-grade Squamous Intraepithelial Lesion / Anal High-Grade Squamous Intraepithelial Lesions / Anal HPV Infection / Anal HSIL 1 2 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Treatment AIN 2/3 / Anal High-Grade Squamous Intraepithelial Lesions / Anal Intraepithelial Neoplasia (AIN) / Anal Precancerous Condition / Human Papilloma Virus (HPV) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.27 mg/mL ALOGPS logP 2.52 ALOGPS logP 3.11 Chemaxon logS -2.4 ALOGPS pKa (Strongest Basic) -4.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 53.99 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 68.68 m3·mol-1 Chemaxon Polarizability 29.43 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 165.5460604 predictedDarkChem Lite v0.1.0 [M-H]- 166.4608604 predictedDarkChem Lite v0.1.0 [M-H]- 160.9841 predictedDeepCCS 1.0 (2019) [M+H]+ 166.2310604 predictedDarkChem Lite v0.1.0 [M+H]+ 166.9595604 predictedDarkChem Lite v0.1.0 [M+H]+ 162.8929 predictedDeepCCS 1.0 (2019) [M+Na]+ 165.9450604 predictedDarkChem Lite v0.1.0 [M+Na]+ 166.5740604 predictedDarkChem Lite v0.1.0 [M+Na]+ 168.67989 predictedDeepCCS 1.0 (2019)
Enzymes
1. DetailsCytochrome P450 2B6
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Hedrich WD, Hassan HE, Wang H: Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425. doi: 10.1016/j.apsb.2016.07.016. Epub 2016 Aug 9. [Article]
- Xing J, Kirby BJ, Whittington D, Wan Y, Goodlett DR: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab Dispos. 2012 Sep;40(9):1757-64. doi: 10.1124/dmd.112.045765. Epub 2012 Jun 7. [Article]
- Flockhart Table of Drug Interactions [Link]
Drug created at October 21, 2016 03:33 / Updated at June 12, 2021 10:55